Last reviewed 01/2018
Donepezil drug is indicated in the symptomatic treatment of mild to moderate Alzheimer's disease (AD).
- acetylcholinesterase (AChE) inhibitors increase the concentration of acetylcholine at sites of neurotransmission
- donepezil is a specific and reversible inhibitor of AChE, licensed in the UK at a dosage of 5 mg/day and 10 mg/day. It is licensed for the symptomatic treatment of people with mild to moderately severe Alzheimer's dementia
See NICE guidance for use in treatment of Alzheimer's disease.
- donepezil improves cognitive outcomes in patients with Alzheimer's disease (AD). However evidence suggests that in patients with AD, donepezil has no significant beneficial effect for treating agitation, a common associated symptom (2)
NICE guidance - cholinesterase inhibitors ( donepezil , galantamine , rivastigmine ) and memantine for the treatment of Alzheimer's disease